ARRY  Array Biopharma Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

1.87B

Vuru Grade

15.85/100

Current Price

$11.12
-0.13 (-1.16%)

Company Metrics

  • P/E 3010
  • P/S 59.39
  • P/B 74.39
  • EPS -0.70
  • Cash ROIC -66.39%
  • Cash Ratio 2.10
  • Dividend 0 / N/A %
  • Avg. Vol. 4.13M
  • Shares 142.96M
  • Market Cap. 1.87B

Company Description

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer, inflammatory, and metabolic diseases in North America, Europe, and Asia Pacific. Its programs under development pipeline include ARRY-403, a glucokinase activator for Type 2 diabetes, that is in a Phase 1 multiple ascending dose tria... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Why Array BioPharma Inc Stock Surged 108.3% in 2016
Motley Fool - Jan 9, 2017
Cancer-focused Array Biopharma Inc (NASDAQ:ARRY) delighted investors with a stellar 108.3% gain last year, according to data from S&P Global Market Intelligence.
Analytical Overview of Array BioPharma Inc. (NASDAQ:ARRY) - FactsReporter
Array BioPharma Inc. (ARRY) Breaks into New 52-Week High on January 18 Session
Equities.com - 20 hours ago
Shares of Array BioPharma Inc. (ARRY) broke into a new 52-week high yesterday, hitting a peak of $11.65. Shares closed at $11.25 after opening at $11.15 for a move of 0.09%.
The Array BioPharma Inc. (ARRY) Stake Maintained by State of New Jersey Common ... - DailyQuint
Array BioPharma Inc. (ARRY) Given a $15.00 Price Target at Piper Jaffray Companies - Sports Perspectives
Traders Watch list: Southwestern Energy Company (NYSE:SWN), Array BioPharma ...
FactsReporter - 3 hours ago
The company announced its last quarter financial performance results on 10/20/2016. Southwestern Energy Company (NYSE:SWN) belongs to Oils-Energy sector that surged 0.1% in value when last trading session closed at $9.69.
The 6-Figure Options Bet on Soaring Array Biopharma Inc (ARRY)
Schaeffers Research (blog) - Jan 13, 2017
Array Biopharma Inc (NASDAQ:ARRY) has had an exciting week, with buyout buzz fueling an earlier rally, which put the shares above a key retracement level.
Array BioPharma Inc. (ARRY) Soars 7.52% on January 13 - Equities.com
Array BioPharma (ARRY) Jumps: Stock Adds 7.5% in Session
Yahoo Finance - Jan 16, 2017
Array BioPharma Inc. ARRY was a big mover last session, as the company saw its shares rise over 7% on the day. The move came on solid volume with far more shares changing hands than in a normal session.
Array BioPharma Inc. (ARRY) Breaks into New 52-Week High on January 03 Session
Equities.com - Jan 3, 2017
Shares of Array BioPharma Inc. (ARRY) broke into a new 52-week high yesterday, hitting a peak of $9.12. Shares closed at $8.56 after opening at $9.00 for a move of -2.62%.
Most Active Stock: Array BioPharma Inc. (NASDAQ:ARRY) - FactsReporter
Traders are Keeping Track of Technicals on Shares of Array BioPharma Inc. (ARRY)
Yankee Analysts - Jan 18, 2017
Array BioPharma Inc. (ARRY) currently has a 14-day Commodity Channel Index (CCI) of 272.21. Dedicated investors may choose to use this technical indicator as a stock evaluation tool.
Inside the Numbers: Checking on Shares of Array BioPharma Inc. (NASDAQ:ARRY)
Marion Business Daily - 1 hour ago
Investors keeping an eye on shares of Array BioPharma Inc. (NASDAQ:ARRY) may be analyzing the company's FCF or Free Cash Flow.
Commit To Purchase Array BioPharma At $4, Earn 13.8% Using Options
Nasdaq - Dec 22, 2016
Investors considering a purchase of Array BioPharma Inc. (Symbol: ARRY) shares, but tentative about paying the going market price of $8.60/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Stock Returns: Array BioPharma Inc (NASDAQ:ARRY) is Beating Arena ... - CML News
Array BioPharma Inc. (ARRY) Receives An Update From Brokers - The De Soto Edge
Array BioPharma secures $20M in financing
BizWest Media - Dec 27, 2016
BOULDER - Array BioPharma Inc. (Nasdaq: ARRY), a Boulder-based biopharmaceutical company, has secured $20 million in financing from Silicon Valley Bank, according to a filing with the U.S.